Compare CPHC & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHC | ICCC |
|---|---|---|
| Founded | 1994 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.1M | 93.1M |
| IPO Year | 2016 | 1995 |
| Metric | CPHC | ICCC |
|---|---|---|
| Price | $15.93 | $10.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 809.0 | ★ 7.5K |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | ★ 53.85 |
| EPS | N/A | ★ 0.41 |
| Revenue | ★ $59,227,000.00 | $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $523.00 | ★ $25.80 |
| Revenue Growth | 0.14 | ★ 51.64 |
| 52 Week Low | $14.39 | $4.52 |
| 52 Week High | $16.84 | $12.10 |
| Indicator | CPHC | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 55.33 | 51.84 |
| Support Level | $15.25 | $9.45 |
| Resistance Level | $16.17 | $10.82 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 87.06 | 51.36 |
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the real estate development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.